Sodium oligomannate
Phase 3Small molecule
Sodium oligomannate is one of 83 small molecule programs targeting Alzheimer's Disease. It is currently in Phase 3.
2
Indications
3
Total Trials
3
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
242 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
HLX10
Shanghai Henlius BiotechPhase 3
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 3
NTQ5082
NNanjing Chia-tai Tianqing Pharmaceutical
Phase 3
Cyclosporin a
NovartisPhase 3
Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 3
Sodium oligomannate
GGreen Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 3
KN057
SSuzhou Alphamab Co., Ltd.
Phase 3
IN-B00009
HHK inno.N Corporation
Phase 3
AD-209
AAddpharma Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Long-term Efficacy and Safety Study of GV-971
Active, not recruiting·GGreen Valley (Shanghai) Pharmaceuticals Co., Ltd.·Phase 4·NCT05181475·800 enrolled
Unspecified1 trial
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
Active, not recruiting·GGreen Valley (Shanghai) Pharmaceuticals Co., Ltd.·Phase 4·NCT05058040·2,500 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sodium oligomannate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details